Metformin with either histamine H2-receptor antagonists or proton pump inhibitors: A polypharmacy recipe for neuropathy via vitamin B12 depletion

Clinical Diabetes

Volumn 33, Issue 2, 2015, Pages 90-95

  Zdilla, Matthew J ^a  

^a WEST LIBERTY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFORMIN; CYANOCOBALAMIN; CYTOCHROME P450; CYTOCHROME P450 2C19; HISTAMINE H2 RECEPTOR ANTAGONIST; MECOBALAMIN; MEPHENYTOIN; METFORMIN; PHENFORMIN; PROTON PUMP INHIBITOR; RANITIDINE;

ARTICLE; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG INDUCED DISEASE; GASTROESOPHAGEAL REFLUX; GENOTYPE; NEUROPATHY; POLYPHARMACY; VITAMIN SUPPLEMENTATION;

EID: 84927932062     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.33.2.90     Document Type: Article

References (64)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211
3. Friedenberg FK, Xanthopoulos M, Foster GD, Richter JE. The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol 2008;103:2111-2122
4. Lee SD, Keum B, Chun HJ, Bak YT. Gastroesophageal reflux disease in type II diabetes mellitus with or without peripheral neuropathy. J Neurogastroenterol Motil 2011;17:274-278
5. Promberger R, Lenglinger J, Riedl O, et al. Gastro-esophageal reflux disease in type 2 diabetics: symptom load and pathophysiologic aspects: a Retro-Pro study. BMC Gastroenterol 2013;13:132
6. Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol 1999;94:919-924
7. Wang X, Pitchumoni CS, Chandrarana K, Shah N. Increased prevalence of symptoms of gastroesophageal reflux diseases in type 2 diabetics with neuropathy. World J Gastroenterol 2008;14:709-712
8. Nishida T, Tsuji S, Tsujii M, et al. Gastroesophageal reflux disease related to diabetes: analysis of 241 cases with type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:258-265
9. 12) and folate deficiency. FASEB J 1993;7:1344-1353
10. 12on methylmalonyl-CoA mutase activity. J Zhejiang Univ Sci B 2012;13:423-437
11. 12-HealthProfessional. Accessed 23 April 2014
12. 12deficiency: a primary demyelinating disease? J Neurol 1988;235:163-164
13. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 1991;70:229-245
14. 12deficiency neurological syndromes: a clinical, MRI and electrodiagnostic study. Electromyogr Clin Neurophysiol 2003;43:57-64
15. 12deficiency neurological syndrome with a short-term follow-up. Nutr Neurosci 2014;17:156-163
16. Ide H, Fujiya S, Asanuma Y, Tsuji M, Sakai H, Agishi Y. Clinical usefulness of intrathecal injection of methylcobalamin in patients with diabetic neuropathy. Clin Ther 1987;9:183-192
17. Yaqub BA, Siddique A, Sulimani R. Effects of methylcobalamin on diabetic neuropathy. Clin Neurol Neurosurg 1992;94:105-111
18. 12on diabetic neuropathy: systematic review of clinical controlled trials. Acta Neurol Taiwan 2005;14:48-54
19. Walker MJ Jr, Morris LM, Cheng D. Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5’-phosphate. Rev Neurol Dis 2010;7:132-139
20. Jacobs AM, Cheng D. Management of diabetic small-fiber neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5’-phosphate. Rev Neurol Dis 2011;8:39-47
21. Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. Intern Med 1999;38:472-475
22. Li G. Effect of mecobalamin on diabetic neuropathies: Beijing Methycobal Clinical Trial Collaborative Group. Zhonghua Nei Ke Za Zhi 1999;38:14-17
23. 12may be more effective than nortriptyline in improving painful diabetic neuropathy. Int J Food Sci Nutr 2009;5:71-76
24. Farvid MS, Homayouni F, Amiri Z, Adelmanesh F. Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation. Diabetes Res Clin Pract 2011;93:86-94
25. Dominguez JC, Ng AR, Damian LF. A prospective, open label, 24-week trial of methylcobalamin in the treatment of diabetic polyneuropathy. J Diabetes Mellit 2012;2:408-412
26. 12, Pantothenic Acid, Biotin, and Choline. Washington, D.C., National Academies Press, 1998
27. Berchtold P, Bolli P, Arbenz U, Keiser G. Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides). Diabetologia 1969;5:405-412
28. 12status of patients on long-term metformin therapy. BMJ 1971;2:685-687
29. 12and intrinsic factor secretion during biguanide therapy. Diabetologia 1983;24:16-18
30. 12status of patients treated with metformin: a cross-sectional cohort study. Br J Diabetes Vasc Dis 2004;4:401-406
31. Pflipsen MC, Oh RC, Saguil A, Seehusen DA, Seaquist D, Topolski R. The prevalence of vitamin B(12) deficiency in patients with type 2 diabetes: a cross-sectional study. J Am Board Fam Med 2009;22:528-534
32. 12deficiency: is it necessary? Pract Diabetes 2001;28:302-304
33. Calvo Romero JM, Ramiro Lozano JM. Vitamin B(12) in type 2 diabetic patients treated with metformin. Endocrinol Nutr 2012;59:487-490
34. 12deficiency, hyperhomocysteinemia and vascular complications in patients with type 2 diabetes. Endocr J 2013;60:1275-1280
35. 12and folic acid: a cross-sectional study in patients with type 2 diabetes mellitus. J Med Assoc Thai 2004;87:780-787
36. Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006;166:1975-1979
37. Wile DJ, Toth C. Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 2010;33:156-161
38. 12and homocysteine status during pregnancy in the metformin in gestational diabetes trial: responses to maternal metformin compared with insulin treatment. Diabetes Obes Metab 2013;15:660-667
39. 12deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med 2013;59:253-257
40. 12absorption in diabetics on biguanides. Diabetologia 1977;13:187-193
41. 12level in serum of diabetics receiving long-term buformin therapy. Z Gesamte Inn Med 1981;36:226-228
42. 12malabsorption induced by metformin. Diabetes Care 2000;23:1227-1231
43. Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J Clin Epidemiol 2001;54:531-534
44. 12requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003;37:490-493
45. 12deficiency in older adults. J Clin Epidemiol 2004;57:422-428
46. DeVault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009;6:524-532
47. 12deficiency. JAMA 2013;310:2435-2442
48. Steinberg WM, King CE, Toskes PP. Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration. Dig Dis Sci 1980;25:188-191
49. 12. Scand J Gastroenterol 1982;17:129-131
50. Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988;3:430-448
51. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 2002;36:812-816
52. Kirch W, Hoensch H, Janisch HD. Interactions and non-interactions with ranitidine. Clin Pharmacokinet 1984;9:493-510
53. 12. Gastroenterol Clin Biol 1983;7:381-384
54. 12levels in patients with Zollinger-Ellison syndrome. Am J Med 1998;104:422-430
55. 12deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121
56. 12status in older adults? J Am Med Dir Assoc 2008;9:162-167
57. Rozgony NR, Fang C, Kuczmarski MF, Bob H. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? J Nutr Elder 2010;29:87-99
58. Festen HP. Intrinsic factor secretion and cobalamin absorption: physiology and pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl 1991;188:1-7
59. 12absorption. Ann Pharmacother 1992;26:1283-1286
60. 12in patients on long-term omeprazole treatment. Aliment Pharmacol Ther 1999;13:453-458
61. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among U.S. adults, 1999-2008. JAMA 2010;303:235-241
62. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012;5:219-232
63. Drugs.com. U.S. pharmaceutical sales-2013. Available from http://www.drugs.com/stats/top100/2013/sales. Accessed 23 April 2014
64. Long AN, Atwell CL, Yoo W, Solomon SS. Vitamin B(12) deficiency associated with concomitant metformin and proton pump inhibitor use. Diabetes Care 2012;35:e84